X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (40) 40
animals (37) 37
humans (33) 33
index medicus (30) 30
rats (26) 26
endocrinology & metabolism (24) 24
middle aged (23) 23
male (22) 22
aged (20) 20
rats, wistar (18) 18
osteoporosis (14) 14
postmenopausal women (14) 14
vasopressin (12) 12
osteoporosis, postmenopausal - drug therapy (11) 11
raloxifene (11) 11
raloxifene hydrochloride - therapeutic use (11) 11
time factors (11) 11
analysis (10) 10
cardiac & cardiovascular systems (9) 9
engineering, electrical & electronic (9) 9
pharmacology & pharmacy (9) 9
amino acid sequence (8) 8
bone-mineral density (8) 8
diabetes mellitus (8) 8
estrogen (8) 8
molecular sequence data (8) 8
nitric oxide (8) 8
risk (8) 8
swine (8) 8
teriparatide - therapeutic use (8) 8
treatment outcome (8) 8
turnover (8) 8
bone density - drug effects (7) 7
cell biology (7) 7
disease (7) 7
ovariectomy (7) 7
parathyroid-hormone 1-34 (7) 7
research article (7) 7
sus scrofa (7) 7
teriparatide (7) 7
therapy (7) 7
adult (6) 6
alendronate - therapeutic use (6) 6
arginine vasopressin - pharmacology (6) 6
disease models, animal (6) 6
double-blind method (6) 6
medical research (6) 6
medicine, experimental (6) 6
mineral density (6) 6
orthopedics (6) 6
physics, applied (6) 6
prospective studies (6) 6
selective estrogen receptor modulators - therapeutic use (6) 6
article subject (5) 5
biochemistry & molecular biology (5) 5
biophysics (5) 5
bone density conservation agents - therapeutic use (5) 5
care and treatment (5) 5
cytology (5) 5
diabetes (5) 5
diabetes mellitus, type 2 - drug therapy (5) 5
dose-response relationship, drug (5) 5
expression (5) 5
glucose (5) 5
health aspects (5) 5
heart (5) 5
inflammation (5) 5
myocardial infarction - pathology (5) 5
myocardium - pathology (5) 5
ng-nitroarginine methyl ester - pharmacology (5) 5
nitric oxide synthase - metabolism (5) 5
peripheral vascular disease (5) 5
physiology (5) 5
postmenopause (5) 5
raloxifene hydrochloride - pharmacology (5) 5
risk factors (5) 5
studies (5) 5
type 2 diabetes (5) 5
vertebral fracture (5) 5
alendronate (4) 4
arginine vasopressin - analogs & derivatives (4) 4
arginine vasopressin - metabolism (4) 4
blood pressure (4) 4
blood pressure - drug effects (4) 4
cardiology (4) 4
cells, cultured (4) 4
coronary angiography (4) 4
enzyme-linked immunosorbent assay (4) 4
estrogens - deficiency (4) 4
fasting (4) 4
follow-up (4) 4
gastric mucosa - pathology (4) 4
glucagon-like peptides - analogs & derivatives (4) 4
heart failure (4) 4
hematology (4) 4
heme oxygenase - metabolism (4) 4
in vitro techniques (4) 4
injury (4) 4
insulin (4) 4
insulin resistance (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Gyöngyösi, Mariann and Gyöngyösi, Mariann and Wojakowski, Wojciech and Wojakowski, Wojciech and Lemarchand, Patricia and Lemarchand, Patricia and Lunde, Ketil and Lunde, Ketil and Tendera, Michal and Tendera, Michal and Bartunek, Jozef and Bartunek, Jozef and Marban, Eduardo and Marban, Eduardo and Assmus, Birgit and Assmus, Birgit and Henry, Timothy D and Henry, Timothy D and Traverse, Jay H and Traverse, Jay H and Moyé, Lemuel A and Moyé, Lemuel A and Sürder, Daniel and Sürder, Daniel and Corti, Roberto and Corti, Roberto and Huikuri, Heikki and Huikuri, Heikki and Miettinen, Johanna and Miettinen, Johanna and Wöhrle, Jochen and Wöhrle, Jochen and Obradovic, Slobodan and Obradovic, Slobodan and Roncalli, Jérome and Roncalli, Jérome and Malliaras, Konstantinos and Malliaras, Konstantinos and Pokushalov, Evgeny and Pokushalov, Evgeny and Romanov, Alexander and Romanov, Alexander and Kastrup, Jens and Kastrup, Jens and Bergmann, Martin W and Bergmann, Martin W and Atsma, Douwe E and Atsma, Douwe E and Diederichsen, Axel and Diederichsen, Axel and Edes, Istvan and Edes, Istvan and Benedek, Imre and Benedek, Imre and Benedek, Theodora and Benedek, Theodora and Pejkov, Hristo and Pejkov, Hristo and Nyolczas, Noemi and Nyolczas, Noemi and Pavo, Noemi and Pavo, Noemi and Bergler-Klein, Jutta and Bergler-Klein, Jutta and Pavo, Imre J and Pavo, Imre J and Sylven, Christer and Sylven, Christer and Berti, Sergio and Berti, Sergio and Navarese, Eliano P and Navarese, Eliano P and Maurer, Gerald and Maurer, Gerald and ACCRUE Investigators
Circulation research, ISSN 0009-7330, 04/2015, Volume 116, Issue 8, pp. 1346 - 1360
Journal Article
Oxidative Medicine and Cellular Longevity, ISSN 1942-0900, 2015, Volume 2015, pp. 429713 - 7
Journal Article
Oxidative Medicine and Cellular Longevity, ISSN 1942-0900, 2015, Volume 2015, pp. 876805 - 9
Journal Article
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 409 - 418
Aims: To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in patients with type 2 diabetes by subgroups of gender, duration of diabetes and... 
GLP | type 2 diabetes | dulaglutide | 1 analogue | GLP-1 | GLP-1 analogue | METFORMIN | METAANALYSIS | EFFICACY | SAFETY | EXENATIDE | OPEN-LABEL | PHASE-3 | NON-INFERIORITY | TRIAL | LIRAGLUTIDE | ENDOCRINOLOGY & METABOLISM | Glycated Hemoglobin A - analysis | Nausea - chemically induced | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Diarrhea - chemically induced | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Female | Weight Gain - drug effects | Immunoglobulin Fc Fragments - therapeutic use | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Blood Glucose - analysis | Drug Administration Schedule | Insulin - administration & dosage | Sex Characteristics | Glucagon-Like Peptides - adverse effects | Vomiting - chemically induced | Diabetes Mellitus, Type 2 - blood | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Type 2 diabetes | Glycosylated hemoglobin | Medicine, Experimental | Medical research | Blood sugar | Analysis | Subpopulations | Fasting | Glucagon | Diabetes mellitus | Body weight | Clinical trials | Body weight loss | Gender | Hypoglycemia | Insulin | Hemoglobin | Diabetes | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | GLP‐1 analogue | GLP‐1 | Original
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2018, Volume 20, Issue 6, pp. 1490 - 1498
Aims: Patients with a type-2-diabetes (T2D) phenotype positive for glutamic acid decarboxylase antibodies (GADA) represent the majority of cases of latent... 
antidiabetic drug | type 1 diabetes | GLP‐1 analogue | dulaglutide | incretin therapy | AUTOANTIBODIES | PHENOTYPE | INHIBITOR SITAGLIPTIN | PREVALENCE | BETA-CELL FUNCTION | INSULIN | GLP-1 analogue | GENETIC-CHARACTERISTICS | ENDOCRINOLOGY & METABOLISM | ONCE-WEEKLY DULAGLUTIDE | DOUBLE-BLIND | TYPE-2 | Sitagliptin Phosphate - administration & dosage | Insulin Glargine - adverse effects | Latent Autoimmune Diabetes in Adults - blood | Double-Blind Method | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Treatment Outcome | Immunoglobulin Fc Fragments - administration & dosage | Glucagon-Like Peptides - adverse effects | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Female | Blood Glucose - metabolism | Glucagon-Like Peptides - analogs & derivatives | Hypoglycemic Agents - adverse effects | Immunoglobulin Fc Fragments - adverse effects | Latent Autoimmune Diabetes in Adults - drug therapy | Recombinant Fusion Proteins - administration & dosage | Sitagliptin Phosphate - adverse effects | Adults | Glutamate | Blood sugar | Type 1 diabetes | Analysis | Glutamic acid | Phenotypes | Diabetes mellitus | Clinical trials | Glutamate decarboxylase | Diabetes | Autoimmune diseases | Patients | Enzyme-linked immunosorbent assay
Journal Article